Ankit Mahadevia, CEO and President at Spero Therapeutics, Inc. (SPRO), sold 29,105 shares at $14.33 ($416K) on 2020-06-23, disclosed to the SEC on 2020-06-29.
Open-market sale of $416k SPRO by CEO and President. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.30 | 2,613 | $37K | 9.0% |
| 2 | $14.33 | 8,045 | $115K | 27.7% |
| 3 | $14.33 | 8,045 | $115K | 27.7% |
| 4 | $14.28 | 3,880 | $55K | 13.3% |
| 5 | $14.28 | 3,880 | $55K | 13.3% |
| 6 | $14.25 | 2,642 |
| $38K |
| 9.0% |
| Total | $14.31 avg | 29,105 | $416K | 100% |
| Filing → |
| SPRO | SELL | 2024-08-29 | $8K | — | Filing → |
| SPRO | SELL | 2024-02-05 | $175K | — | Filing → |
| SPRO | SELL | 2023-08-30 | $11K | — | Filing → |